Honeybear Biosciences Wins ABEA Recognition Showcasing ADC/ARC R&D Strength on the Global Stage
On March 11, 2026, at the Asia Pacific Biopharma Excellence Awards (ABEA) ceremony held in Singapore, Honeybear Biosciences was represented by Vice Chairwoman Sarina Lin and CEO Dr. Simon, Shih-Hsien, Chuang, to accept the award for “Most Promising ADC Clinical Candidate in Taiwan.” This recognition highlights the company’s innovation and clinical potential in the development of Antibody-Drug Conjugates (ADC) and Antibody-Radionuclide Conjugates (ARC). The award not only reinforces the company’s strong track record in R&D capability but also highlights Taiwan’s growing competitiveness in next-generation ADC development.
During the concurrent ADC Asia Congress, Dr. Chuang was invited to deliver a keynote speech, introducing the company’s proprietary CoNectar® site-specific glycan conjugation platform and sharing the latest progress of its innovative ARC. The candidate has successfully completed key efficacy and mechanism-of-action studies and is expected to enter formal toxicology studies, advancing steadily toward an Investigational New Drug (IND) application.
In addition, Dr. Chuang was invited to serve as a panel moderator for a roundtable discussion on “Navigating Investment in ADCs Securing Funding for Innovation in Asia.” He shared his insights on fundraising and R&D strategies in Taiwan, facilitating meaningful international exchange. Honeybear Biosciences stated that it will continue to expand global collaborations and advance its technology platforms, accelerating the development of innovative therapies toward clinical application and international markets.
Please visit the related news link for more details：
On March 11, 2026, at the Asia Pacific Biopharma Excellence Awards (ABEA) ceremony held in Singapore, Honeybear Biosciences was represented by Vice Chairwoman Sarina Lin and CEO Dr. Simon, Shih-Hsien, Chuang, to accept the award for “Most Promising ADC Clinical Candidate in Taiwan.” This recognition highlights the company’s innovation and clinical potential in the development of Antibody-Drug Conjugates (ADC) and Antibody-Radionuclide Conjugates (ARC). The award not only reinforces the company’s strong track record in R&D capability but also highlights Taiwan’s growing competitiveness in next-generation ADC development.
During the concurrent ADC Asia Congress, Dr. Chuang was invited to deliver a keynote speech, introducing the company’s proprietary CoNectar® site-specific glycan conjugation platform and sharing the latest progress of its innovative ARC. The candidate has successfully completed key efficacy and mechanism-of-action studies and is expected to enter formal toxicology studies, advancing steadily toward an Investigational New Drug (IND) application.
In addition, Dr. Chuang was invited to serve as a panel moderator for a roundtable discussion on “Navigating Investment in ADCs Securing Funding for Innovation in Asia.” He shared his insights on fundraising and R&D strategies in Taiwan, facilitating meaningful international exchange. Honeybear Biosciences stated that it will continue to expand global collaborations and advance its technology platforms, accelerating the development of innovative therapies toward clinical application and international markets.
Please visit the related news link for more details：
- 鉅亨網 https://hao.cnyes.com/post/238199
- 匯流新聞網 https://cnews.com.tw/204260318a03/
- 商傳媒 https://pse.is/8ue84v
- 蕃新聞 https://n.yam.com/Article/20260318414581
- 民生電子報 https://lifenews.com.tw/483805
- 奧丁丁新聞 https://news.owlting.com/articles/1293957
- 台灣電報 https://enn.tw/699361/
- 墨新聞 https://more-news.tw/555770/
- AMM亞洲心動娛樂 https://ammtw.com/110860
- 獨家報導 https://pse.is/8uee9h
- 理財周刊 https://www.moneyweekly.com.tw/ArticleData/Info/Article/214945
- Life生活網 https://life.tw/?app=view&no=2977726
- 警政時報 https://www.tcpttw.com/other/other_industrial/2026/03/18/255074/
- 台灣線報 https://twline365.com/2026/03/1119473/
- YAM蕃新聞 https://pse.is/8ukx4s
- OwlNews https://pse.is/8ukx65
- 台灣調查網 https://pse.is/8ukx6y
- 樂聯網 https://leho.com.tw/archives/267338
- 記者爆料網 https://new-reporter.com/news/156331/
- 台北郵報 https://taipeipost.org/346278/
- 是新聞 https://pse.is/8ukyd5
- 民聲新聞 https://91postnews.com/sunmedia/81005
- 行銷人 https://pse.is/8ukygt
- 工商時報 https://www.ctee.com.tw/news/20260319700690-431205
Honeybear Biosciences was represented by Vice Chairwoman Sarina Lin (Middle) and CEO Dr. Simon, Shih-Hsien, Chuang (Right) to accept the ABEA award—”Most Promising ADC Clinical Candidate in Taiwan” in Singapore.
Dr. Chuang was invited to deliver a keynote speech and to serve as a panel moderator for a roundtable discussion and experience sharing.
